Australia's most trusted
source of pharma news
Friday, 8 May 2026
Sales of Novo Nordisk's obesity pill has broken records in the US since launching in January and now its heading to Australia setting the stage for new turf war with Lilly which submitted its own oral GLP-1 for evaluation to the regulator four months ago.